2. Search Result
Search Result
Pathways Recommended: Anti-infection
Results for "

human immunodeficiency virus infection

" in MedChemExpress (MCE) Product Catalog:

43

Inhibitors & Agonists

1

Fluorescent Dyes

3

Peptides

6

Inhibitory Antibodies

4

Natural
Products

2

Isotope-Labeled Compounds

2

Oligonucleotides

Targets Recommended:
Cat. No. 상품명 Target 연구분야 Chemical Structure
  • HY-111964
    Lenacapavir
    Maximum Cited Publications
    19 Publications Verification

    GS-6207

    		 HIV Infection
    Lenacapavir (GS-6207) is an HIV-1 capsid inhibitor. Lenacapavir binds to the interface between capsid hexamers and CA monomers, disrupts capsid assembly and viral maturation, inhibits nuclear translocation of HIV-1 DNA, interferes with CA-mediated protein-protein interactions, reduces the formation of 2-LTR circles and pre-integration proviruses, induces aberrant capsids, and decreases the production of mature HIV-1. Lenacapavir exhibits activity against a variety of HIV-1 subtypes and clinical isolates. Lenacapavir is applicable to research related to human immunodeficiency virus type 1 (HIV-1) infection .
    Lenacapavir
  • HY-109137
    Selgantolimod
    1 Publications Verification

    GS-9688

    		 Toll-like Receptor (TLR) HBV Infection
    Selgantolimod (GS-9688) is an orally active, potent and selective toll-like receptor 8 (TLR8) agonist for the treatment of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infection .
    Selgantolimod
  • HY-78726
    Fosamprenavir
    4 Publications Verification

    Amprenavir phosphate; GW 433908

    		 Drug Intermediate HIV HIV Protease Infection
    Fosamprenavir is an orally active inhibitor targeting HIV-1 protease and is a prodrug of Amprenavir (HY-17430). Fosamprenavir is hydrolyzed into Amprenavir (VX-478) by cell phosphatases in the intestinal epithelium. Amprenavir binds to the active site of HIV-1 protease, preventing the processing of viral gag and gag-pol polyprotein precursors, thereby inhibiting the formation of mature infectious virus particles and exerting anti-HIV-1 infection activity. Fosamprenavir can be used for the study of human immunodeficiency virus (HIV-1) infection .
    Fosamprenavir
  • HY-N2571
    Corydine

    		Reverse Transcriptase HIV Opioid Receptor Infection Neurological Disease Cancer
    Corydine is a HIV-1 reverse transcriptase inhibitor and μ-opioid receptor (MOR) agonist, with an IC50 of 356.7 μg/mL against HIV-1 reverse transcriptase, an EC50 of 0.51 μM for MOR, and a Ki of 2.82 μM for MOR. Corydine produces antinociceptive effects by inhibiting acetic acid-induced writhing behavior in a MOR-dependent manner. Corydine inhibits the proliferation of cancer cells, mitogen-stimulated lymphocytes and IL-2-dependent cells. Corydine can be used in studies related to human immunodeficiency virus infection, visceral pain, leukemia, melanoma, bladder cancer and colon adenocarcinoma .
    Corydine
  • HY-132191
    Pradimicin A

    		Fungal SARS-CoV HIV Infection
    Pradimicin A is a potent antifungal agent with a minimum inhibitory concentration (MIC) of 4 μg/mL against Candida rugosa. Pradimicin A exhibits antiviral activity against SARS-CoV, human immunodeficiency virus (HIV) and other enveloped viruses. Pradimicin A exerts its fungicidal activity through a Ca 2+-dependent mechanism, which induces fungal lysis. Pradimicin A can be used in research related to fungal infections, HIV infections and COVID-19 .
    Pradimicin A
  • HY-17431
    Fosamprenavir Calcium Salt
    4 Publications Verification

    GW433908G

    		 Drug Intermediate HIV HIV Protease Infection
    Fosamprenavir Calcium Salt (GW433908G) is an orally active inhibitor targeting HIV-1 protease and is a prodrug of Amprenavir (HY-17430). Fosamprenavir Calcium Salt is hydrolyzed into Amprenavir (VX-478) by cell phosphatases in the intestinal epithelium. Amprenavir binds to the active site of HIV-1 protease, preventing the processing of viral gag and gag-pol polyprotein precursors, thereby inhibiting the formation of mature infectious virus particles and exerting anti-HIV-1 infection activity. Fosamprenavir Calcium Salt can be used for the study of human immunodeficiency virus (HIV-1) infection .
    Fosamprenavir Calcium Salt
  • HY-18257
    Rolitetracycline

    		Antibiotic Bacterial Dengue Virus Amyloid-β HIV Integrase Infection Neurological Disease Inflammation/Immunology
    Rolitetracycline is a highly soluble, broad-spectrum antibiotic derived from tetracycline. Rolitetracycline binds to and stabilizes bovine serum albumin, and also inhibits HIV-1 integrase, blocks Aβ fibril formation and suppresses dengue virus proliferation. Rolitetracycline mediates the inhibition of Aβ fibrils via a specific three-dimensional pharmacophore conformation, and exerts bacteriostatic and bactericidal activities. Rolitetracycline acts synergistically with Penicillin G (HY-N7139) or Cephalothin (HY-B1275A) to alter the effects on microbial growth. Rolitetracycline serves as an important tool compound for the study of bacterial infections (urinary tract infections, sepsis), HIV-1 and dengue virus infections, as well as Alzheimer's disease .
    Rolitetracycline
  • HY-111964A
    Lenacapavir sodium
    Maximum Cited Publications
    19 Publications Verification

    GS-6207 sodium

    		 HIV Infection
    Lenacapavir (GS-6207) sodium is an HIV-1 capsid inhibitor. Lenacapavir sodium binds to the interface between capsid hexamers and CA monomers, disrupts capsid assembly and viral maturation, inhibits nuclear translocation of HIV-1 DNA, interferes with CA-mediated protein-protein interactions, reduces the formation of 2-LTR circles and pre-integration proviruses, induces aberrant capsids, and decreases the production of mature HIV-1. Lenacapavir sodium exhibits activity against a variety of HIV-1 subtypes and clinical isolates. Lenacapavir sodium is applicable to research related to human immunodeficiency virus type 1 (HIV-1) infection .
    Lenacapavir sodium
  • HY-149906
    Trecovirsen

    GEM91

    		 HIV Infection
    Trecovirsen is an antiviral agent targeting HIV gag mRNA, which hybridizes with complementary HIV gag mRNA at the initiation site. Trecovirsen induces a reversible, dose-dependent prolongation of activated partial thromboplastin time via its polyanionic properties. Trecovirsen is applicable to research related to HIV infection .
    Trecovirsen
  • HY-171692
    G3-YSD

    		Cyclic GMP-AMP Synthase IFNAR STING Infection
    G3-YSD is a cGAS agonist. G3-YSD directly interacts with cGAS to enhance its enzymatic activity, promote the conversion of ATP and GTP into cGAMP, and trigger STING-dependent IFN-α/β secretion. G3-YSD acts as a viral mimic to replace actual viral DNA . G3-YSD is applicable to research related to long COVID and type 1 human immunodeficiency virus infection .
    G3-YSD
  • HY-106958
    Talviraline

    HBY 097

    		 HIV Reverse Transcriptase Infection
    Talviraline is a non-nucleoside reverse transcriptase (NNRT) inhibitor that is primarily used to inhibit the replication of human immunodeficiency virus type 1 (HIV-1). Talviraline inhibits the viral replication process by binding to a specific site of HIV-1 reverse transcriptase (RT). Talviraline can be used to study the potential countermeasures and safety of HIV-1 infection .
    Talviraline
  • HY-P990835
    Anti-LFA-1α/CD11a Antibody (TS-1/22.1.1.13)

    		Integrin Infection Inflammation/Immunology
    Anti-LFA-1α/CD11a Antibody (TS-1/22.1.1.13) is a kind of mouse IgG1 chimeric antibody inhibitor, targeting to human LFA-1α/CD11a. Anti-LFA-1α/CD11a Antibody (TS-1/22.1.1.13) reacts with human LFA-1α (lymphocyte function-associated antigen 1 alpha) also known as integrin alpha L chain and CD11a. Anti-LFA-1α/CD11a Antibody (TS-1/22.1.1.13) can be used for the researches of immunology and infection, such as human immunodeficiency virus (HIV) .
    Anti-LFA-1α/CD11a Antibody (TS-1/22.1.1.13)
  • HY-78726S
    Fosamprenavir-d4

    Amprenavir phosphate-d4; GW 433908-d4

    		 Isotope-Labeled Compounds Drug Intermediate HIV HIV Protease Infection
    Fosamprenavir-d4 is the Deuterium-labeled Fosamprenavir (HY-78726). Fosamprenavir is an orally active inhibitor targeting HIV-1 protease and is a prodrug of Amprenavir (HY-17430). Fosamprenavir is hydrolyzed into Amprenavir (VX-478) by cell phosphatases in the intestinal epithelium. Amprenavir binds to the active site of HIV-1 protease, preventing the processing of viral gag and gag-pol polyprotein precursors, thereby inhibiting the formation of mature infectious virus particles and exerting anti-HIV-1 infection activity. Fosamprenavir can be used for the study of human immunodeficiency virus (HIV-1) infection .
    Fosamprenavir-d4
  • HY-178201
    JLJ648

    		HIV Pyroptosis Infection
    JLJ648 is a Gag-Pol dimerizer with antiviral activity. JLJ648 can inhibit HIV replication and induce infected cell pyroptosis. JLJ648 can be used for the research of infection, such as HIV (human immunodeficiency virus) .
    JLJ648
  • HY-P35433
    Tifuvirtide

    T-1249

    		 HIV Inflammation/Immunology
    Tifuvirtide (T-1249) is a peptide human immunodeficiency virus type-1 (HIV-1) fusion inhibitor. Tifuvirtide is a synthetically designed hybrid retroviral envelope polypeptide. Tifuvirtide has antiretroviral activity. Tifuvirtide can be used for the research of HIV infection .
    Tifuvirtide
  • HY-139158
    Ainuovirine

    		HIV Infection
    Ainuovirine is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI). Ainuovirine inhibits HIV replication by non-competitively binding to HIV reverse transcriptase and blocking the reverse transcription process of viral RNA. Ainuovirine can be used for human immunodeficiency virus (HIV) type 1 infection .
    Ainuovirine
  • HY-P2251
    T-peptide

    		HIV Microtubule/Tubulin Infection Inflammation/Immunology Cancer
    T-peptide, a Tuftsin analog, can be used for the research of human immunodeficiency virus (HIV) infection. T-peptide prevents cellular immunosuppression and improves survival rate in septic mice. T-peptide also can inhibit the growth of residual tumor cells after surgical resection .
    T-peptide
  • HY-B0155
    Vicriviroc

    SCH 417690; SCH-D; MK-7690 free base

    		 CCR HIV Infection Cancer
    Vicriviroc (SCH 417690) is an orally active CCR5 antagonist with the IC50 of 10 nM, and also inhibts MIP-1α and intracellular calcium release induced by the ligand RANTES (10 nM) with the IC50 values of 0.91 nM and 16 nM,,respectively. Vicriviroc can inhibits human immunodeficiency virus type 1 (HIV-1) infection, and can also used for study of cancer .
    Vicriviroc
  • HY-P991541
    HGS101

    		CCR HIV Infection
    HGS101 is a fully human CCR5 monoclonal antibody with high affinity to CCR5. HGS101 binds to the 2nd extracellular loop (ECL-2) and acts as a signal antagonist. HGS101 restores Maraviroc (HY-13004) inhibition of Maraviroc-resistant HIV-1 infection of PBMCs. HGS101 shows anti-HIV activity by inhibiting CCR5 signaling in simian immunodeficiency virus-uninfected RMs models .
    HGS101
  • HY-D1916A
    ATTO 594 TEA

    		Fluorescent Dye Others
    ATTO 594 TEA is a highly hydrophilic fluorescent dye used to label the outermost position of the glycan moiety of glycosphingolipids to retain the biophysical and biochemical properties of native glycosphingolipids .
    ATTO 594 TEA
  • HY-116252
    (±)-trans-Lamivudine

    		HIV Infection
    (±)-trans-Lamivudine is separated from the salt of (S)-(+) mandelic acid. (±)-trans-Lamivudine forms cocrystals with (S)-BINOL. (±)-trans-Lamivudine is promising for research of human immunodeficiency virus infection .
    (±)-trans-Lamivudine
  • HY-105386
    HI-280

    		HIV Reverse Transcriptase Infection
    HI-280 is a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor. HI-280 can be used for the research of infection .
    HI-280
  • HY-106038
    Acopafant

    Dacopafant; RP 55778

    		 HIV Platelet-activating Factor Receptor (PAFR) Infection
    Acopafant (Dacopafant; RP 55778) is a potent platelet-activating factor antagonist. Acopafant inhibits the induction of human immunodeficiency virus (HIV) expression in chronically infected cells. Acopafant has the potential for the research of HIV infection .
    Acopafant
  • HY-129678
    UK-88947 hydrochloride

    		HIV Protease HIV Infection
    UK-88947 hydrochloride is a protease inhibitor with activity in inhibiting the replication of human immunodeficiency virus HIV-1. UK-88947 hydrochloride can be added to cells before infection to block the early steps of HIV-1 replication. The use of UK-88947 hydrochloride shows its specific inhibitory effect on HIV-1. At the same time, when the virus infects cells, it inhibits the action of viral protease and affects the virus replication process .
    UK-88947 hydrochloride
  • HY-P990843
    Anti-Glycophorin A (type M) Antibody (6A7M)

    		Transmembrane Glycoprotein Infection
    Anti-Glycophorin A (type M) Antibody (6A7M) is a kind of mouse IgG1 κ chimeric antibody inhibitor, targeting to human Glycophorin A (type M). Anti-Glycophorin A (type M) reacts with the human glycophorin A (GPA) M allele also known as CD235a. Anti-Glycophorin A (type M) can be used for the research of infection, such as human immunodeficiency virus (HIV) .
    Anti-Glycophorin A (type M) Antibody (6A7M)
  • HY-78726A
    Fosamprenavir sodium

    Amprenavir phosphate sodium; GW 433908 sodium

    		 Drug Intermediate HIV HIV Protease Infection
    Fosamprenavir sodium is an orally active inhibitor targeting HIV-1 protease and is a prodrug of Amprenavir (HY-17430). Fosamprenavir sodium is hydrolyzed into Amprenavir (VX-478) by cell phosphatases in the intestinal epithelium. Amprenavir binds to the active site of HIV-1 protease, preventing the processing of viral gag and gag-pol polyprotein precursors, thereby inhibiting the formation of mature infectious virus particles and exerting anti-HIV-1 infection activity. Fosamprenavir sodium can be used for the study of human immunodeficiency virus (HIV-1) infection .
    Fosamprenavir sodium
  • HY-182588
    Circulin B

    		Bacterial HIV Dengue Virus Infection
    Circulin B is a macrocyclic plant cyclopeptide. Circulin B functions as a plant defense peptide and exhibits antibacterial and anti-HIV activities. Circulin B has high binding affinity for the envelope protein of dengue virus, showing potential anti-dengue virus activity. Circulin B can be used in studies related to dengue virus infection, human immunodeficiency virus infection and microbial infection .
    Circulin B
  • HY-P990874
    Anti-HIV gp120 Antibody (55-36)

    		HIV Infection
    Anti-HIV gp120 Antibody (55-36) is a kind of mouse IgG1 κ chimeric antibody, targeting to human HIV gp120. Anti-HIV gp120 Antibody (55-36) reacts with human immunodeficiency virus (HIV) envelope glycoprotein 120 (gp120). Anti-HIV gp120 Antibody (55-36) can be used for the research of HIV infection .
    Anti-HIV gp120 Antibody (55-36)
  • HY-B0155B
    Vicriviroc malate

    SCH 417690 malate; SCH-D malate; MK-7690

    		 CCR HIV Infection Cancer
    Vicriviroc (SCH 417690) malate is an orally active CCR5 antagonist with the IC50 of 10 nM, and also inhibts MIP-1α and intracellular calcium release induced by the ligand RANTES (10 nM) with the IC50 values of 0.91 nM and 16 nM,,respectively. Vicriviroc malate can inhibits human immunodeficiency virus type 1 (HIV-1) infection, and can also used for study of cancer .
    Vicriviroc malate
  • HY-78726S2
    Fosamprenavir-13C6

    Amprenavir phosphate-13C6; GW 433908-13C6

    		 Isotope-Labeled Compounds Drug Intermediate HIV HIV Protease Infection
    Fosamprenavir- 13C6 is the 13C-labeled Fosamprenavir (HY-78726). Fosamprenavir is an orally active inhibitor targeting HIV-1 protease and is a prodrug of Amprenavir (HY-17430). Fosamprenavir is hydrolyzed into Amprenavir (VX-478) by cell phosphatases in the intestinal epithelium. Amprenavir binds to the active site of HIV-1 protease, preventing the processing of viral gag and gag-pol polyprotein precursors, thereby inhibiting the formation of mature infectious virus particles and exerting anti-HIV-1 infection activity. Fosamprenavir can be used for the study of human immunodeficiency virus (HIV-1) infection .
    Fosamprenavir-13C6
  • HY-17431R
    Fosamprenavir Calcium Salt (Standard)

    GW433908G (Standard)

    		 Reference Standards Drug Intermediate HIV HIV Protease Infection
    Fosamprenavir Calcium Salt (GW433908G) (Standard) is the analytical standard of Fosamprenavir Calcium Salt (HY-17431R). This product is intended for research and analytical applications. Fosamprenavir Calcium Salt (GW433908G) is an orally active inhibitor targeting HIV-1 protease and is a prodrug of Amprenavir (HY-17430). Fosamprenavir Calcium Salt is hydrolyzed into Amprenavir (VX-478) by cell phosphatases in the intestinal epithelium. Amprenavir binds to the active site of HIV-1 protease, preventing the processing of viral gag and gag-pol polyprotein precursors, thereby inhibiting the formation of mature infectious virus particles and exerting anti-HIV-1 infection activity. Fosamprenavir Calcium Salt can be used for the study of human immunodeficiency virus (HIV-1) infection .
    Fosamprenavir Calcium Salt (Standard)
  • HY-P10429
    RCP168

    		CXCR Infection
    RCP168 is a highly selective and affinity CXCR4 receptor antagonist (IC50=5 nM). RCP168 has a stronger ability than natural chemical factors to inhibit the entry of HIV-1 (human immunodeficiency virus type 1) into host cells via CXCR4 receptors. RCP168 inhibits HIV-1 infection by blocking viral binding sites or inducing receptor internalization. RCP168 can be used to analyze the interaction between CXCR4 receptor and other chemical factor receptors .
    RCP168
  • HY-P990829
    Anti-NKG2D/CD314 Antibody (1D11)

    		C-type Lectin-like Receptors (CTLRs) Infection
    Anti-NKG2D/CD314 Antibody (1D11) is a kind of mouse IgG1 κ chimeric antibody, targeting to human NKG2D/CD314. Anti-NKG2D/CD314 Antibody (1D11) can block the binding of NKG2D to its ligands. Anti-NKG2D/CD314 Antibody (1D11) can be used for the research of infection, such as HIV (human immunodeficiency virus) .
    Anti-NKG2D/CD314 Antibody (1D11)
  • HY-P990848
    Anti-CTLA-4/CD152 Antibody (BN13)

    		CTLA-4 Infection Inflammation/Immunology
    Anti-CTLA-4/CD152 Antibody (BN13) is a kind of mouse IgG2a κ chimeric antibody inhibitor, targeting to human CTLA-4/CD152. Anti-CTLA-4/CD152 Antibody (BN13) can neutralize CTLA-4 (cytotoxic T lymphocyte antigen-4) also known as CD152. Anti-CTLA-4/CD152 Antibody (BN13) can be used for the researches of infection and immunology, such as human immunodeficiency virus (HIV) .
    Anti-CTLA-4/CD152 Antibody (BN13)
  • HY-182316
    P-1946

    		HIV Protease HIV Infection
    P-1946 is a HIV protease inhibitor with a human HIV-1 protease Ki of 2.600 nM. P-1946 has potent and selective in vitro antiviral activity and retains full antiviral activity against HIV isolates resistant to commercially available protease inhibitors. P-1946 can be used for the research of human immunodeficiency virus type 1 (HIV-1) infection .
    P-1946
  • HY-182674
    VGD020

    		Sec61 HIV Flavivirus Neurotensin Receptor Infection Cancer
    VGD020 is a highly potent and selective Sec61 translocon inhibitor . VGD020 suppresses the expression of cell surface CD4 by inhibiting signal peptide-dependent co-translational ER translocation, interferes with the initiation of ER translocation of dengue virus polyprotein, and reduces the expression of Sortilin in breast cancer cells. VGD020 exhibits broad anti-flavivirus and anti-HIV activities. VGD020 can be used in research related to dengue virus infection, Zika virus infection, yellow fever virus infection, human immunodeficiency virus infection, and breast cancer .
    VGD020
  • HY-100083R
    Dolutegravir intermediate-1 (Standard)

    		Reference Standards HIV Others
    Dolutegravir intermediate-1 (Standard) is the analytical standard of Dolutegravir intermediate-1 (HY-100083). This product is intended for research and analytical applications. Dolutegravir intermediate-1 is a synthetic intermediate of Dolutegravir extracted from patent WO 2016125192 A2. Dolutegravir is an integrase inhibitor developed for the treatment of human immunodeficiency virus (HIV)-1 infection.
    Dolutegravir intermediate-1 (Standard)
  • HY-165513
    Niruriside

    		HIV Infection
    Niruriside is a HIV REV/RRE complex inhibitor. Niruriside specifically inhibits the binding interaction between HIV REV protein and RRE RNA, with an IC50 of 3.3 μM, and shows no significant activity against the unrelated R17 capsid protein/operator RNA binding system. At the tested concentrations, Niruriside fails to protect CEM-SS cells from acute HIV-1 infection. Niruriside can be used in the research of human immunodeficiency virus (HIV) infection .
    Niruriside
  • HY-125494A
    Droxinavir

    SC-55389A free base

    		 HIV HIV Protease Infection
    Droxinavir (SC-55389A free base) is an HIV-1 protease inhibitor. Droxinavir binds to the S2 and S2' subsites of HIV-1 protease, and this interaction is regulated by protease amino acid residue 88, where the N88S mutation confers viral resistance. Droxinavir can be used in studies related to human immunodeficiency virus type 1 infection .
    Droxinavir
  • HY-182678
    L-731988

    		HIV Integrase Infection
    L-731988 is an inhibitor targeting HIV-1 integrase. L-731988 inhibits HIV-1 replication by blocking integrase function. L-731988 exhibits ED50 values ranging from 0.5 μM to 3.14 μM against various HIV-1 isolates. L-731988 can be used for the research of human immunodeficiency virus type 1 (HIV-1) infection .
    L-731988
  • HY-126120
    BILA 1906 BS

    		HIV HIV Protease Infection
    BILA 1906 BS is a HIV protease inhibitor. BILA 1906 BS prevents HIV-1 replication via inhibition of viral protease-mediated cleavage of Gag and Gag-Pol polyprotein precursors during virion maturation. BILA 1906 BS blocks maturation of p24 proteins in wild-type HIV-1, impairing polyprotein processing and viral maturation. BILA 1906 BS can be used for the research of human immunodeficiency virus type 1 (HIV-1) infection .
    BILA 1906 BS
  • HY-182514
    BMMP

    		HIV hnRNP Infection Cancer
    BMMP is an anti-HIV-1 agent and hnRNP M modulator. BMMP modulates hnRNP M function to suppress CD44 mRNA expression. BMMP induces abnormal uncoating of the HIV viral core at the post-entry step. BMMP suppresses migration of TGF-β-stimulated lung carcinoma cells. BMMP suppresses HIV-1 reverse transcription and replication without inhibiting virion release. BMMP exerts anti-HIV-1 activity via a mechanism distinct from CA protein-binding heterocyclic compounds. BMMP can be used for the research of human immunodeficiency virus infection and non-small cell lung cancer .
    BMMP
  • HY-183925
    Redoxal

    		HIV Dihydroorotate Dehydrogenase Infection
    Redoxal is a dihydroorotate dehydrogenase (DHODH) inhibitor and anti-HIV-1 agent. Redoxal induces intracellular pyrimidine depletion by inhibiting the de novo pyrimidine biosynthesis pathway, enhances the protein stability of APOBEC3G (A3G), upregulates the abundance of A3G protein in cells and progeny viral particles, thereby strengthening the host endogenous antiviral restriction mediated by A3G . Redoxal selectively targets DHOdehase at the mitochondrial level, with an IC50 of 430 nM for inhibiting DHO oxidation in human mitochondria and an IC50 of 910 nM in rat mitochondria . Redoxal can be used in studies related to HIV-1 infection .
    Redoxal

온라인 문의

Your information is safe with us. * Required Fields.

호칭

  

Country or Region *

고객명 *

 

회사명 *

Department *

     

메일주소 *

 

상품명 *

Cat. No.

  

Requested quantity *

전화번호 *

     

비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: